bioRxiv Science⌕ Search

bioRxiv · 10.64898/2026.10.15.759393

Modified 3rd Generation Synchronization Modulation Electric Field (3m-SMEF) Prevents Ischemia-Reperfusion-Induced Acute Kidney Injury via Targeting Na⁺/K⁺-ATPase

Abstract

Acute kidney injury (AKI) caused by ischemia-reperfusion injury (IRI) remains a major clinical problem with limited therapeutic options. We previously demonstrated that the 3rd-generation Synchronization Modulation Electric Field (SMEF) preserves Na/K-ATPase function during ischemia and protects against kidney injury. In the present study, we substantially modified the 3rd-generation SMEF (3m-SMEF) to further improve/optimize Na/K-ATPase regulation and enhance the protective effects, which was tested both in vitro and in vivo. In HK-2 cells, hypoxia/reoxygenation reduced Na/K-ATPase expression and induced apoptotic and necroptotic signaling, whereas 3m-SMEF restored Na/K-ATPase expression and markedly reduced cell death. In vivo, male and female mice underwent unilateral renal ischemia with or without 3m-SMEF treatment during vascular clamping. At 24 h, 3m-SMEF markedly improved renal function, reducing plasma creatinine by ~90-95% and restoring glomerular filtration rate to near-control levels. Application of the 3m-SMEF also normalized kidney injury markers (KIM-1 and NGAL), preserved renal ATP, and prevented the translocation and loss of Na/K-ATPase expression. The renoprotective effects substantially exceeded those achieved with the previous SMEF platform. These findings demonstrate that 3m-SMEF provides robust protection against ischemic AKI by preserving Na/K-ATPase function and tubular integrity and represents a promising non-pharmacological therapy for ischemic kidney injury.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Hall, N., Zeleznova, N. N., Esquivel, C., Wahbeh, T., Parris, C., Lozonschi, I., Hernandez, N., Wang, L., Chen, W., Liu, R.. 2026-10-21. Modified 3rd Generation Synchronization Modulation Electric Field (3m-SMEF) Prevents Ischemia-Reperfusion-Induced Acute Kidney Injury via Targeting Na⁺/K⁺-ATPase. https://doi.org/10.64898/2026.10.15.759393

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

Speed judgments during smooth pursuit reflect low gain efference copy

During smooth pursuit eye movements, the visual system must compensate for self-generated retinal motion to achieve stable perception of motion in the environment. This compensation primarily depends on an efferent copy of motor commands. Systematically under- or overweighting the strength of efference copy should lead to correlations between eye movement velocity and perceived object velocity. However, previous examinations of these trial-by-trial perceptual correlations have produced mixed results. It remains unclear how effectively the brain compensates for eye movement induced retinal motion during pursuit, and what this reveals about the way efference copy influences perception. To address this, we developed a speed perturbation paradigm in which 29 participants tracked a moving target that underwent brief speed changes. On each trial, we recorded eye velocity along with perceptual judgments of the sign of the speed change (faster or slower) and confidence ratings for those judgments. Across participants, perceptual and oculomotor sensitivity were correlated (r =0.53), but trial-by-trial perceptual and oculomotor responses appeared independent. A logistic regression model incorporating efference copy gain to predict perceptual reports from stimulus speed and eye speed revealed systematic under-compensation for eye movements; faster eye movements were associated with lower changes in perceived speed. Confidence ratings were well-calibrated to perceptual accuracy and showed a consistent negative relationship with eye movement speed. Collectively, these results are consistent with systematic under compensation for eye movements through the use of efference copy during motion perception.

physiology↗

Hemin Triggers Cytoprotective Lipid Droplet Formation in Pulmonary Microvascular Endothelial Cells

Sickle cell disease (SCD) is characterized by chronic and episodic hemolysis, inducing endothelial cell dysfunction and death. Lipid droplets (LDs) accumulate intracellularly in response to stress but the role of LDs in hemin-stressed pulmonary microvascular cells remain unexplored. We hypothesized that LD formation is an adaptive response that improves endothelial cell survival during hemin-induced stress. We utilized cultures of human lung microvascular endothelial cells (hLMVECs) to test this hypothesis. Hemin alone was able to induce LD biogenesis in culture. In response to hemin treatment, we found an increase in cellular death by lactate dehydrogenase (LDH) assay when LD biogenesis was inhibited with a small molecule inhibitor of diacylglycerol acyltransferase 1 (DGAT1), A922500. Induction of LDs by treatment with oleic acid (OA) coupled with hemin resulted in improved endothelial cell survival. Hemin treatment was able to activate p-JNK and p-P38 signaling, while treatment with OA alone could not induce either signaling pathway. Hemin treatment combined with DGAT1 inhibition resulted in an increase in endothelial cell secreted IL-6 and IL-8 levels as measured by enzyme linked immunosorbent assay (ELISA), demonstrating an increase in endothelial cell dysfunction and stress. Induction of LD formation with oleic acid (OA) treatment resulted a reduction in secreted IL-6 and IL-8. Mitochondrial reactive oxygen species (ROS) production was decreased by OA treatment, as evidenced by MitoSOXRed assay. These data suggest that hLMVECs are protected from hemin-induced inflammation and death by the presence of LDs. Further studies are needed to explore the Hemin-LD-Cell Death axis for translational therapeutic use.

physiology↗

AN INTEGRATED HEART-ON-A-CHIP NAM RESOLVES DISTINCT CLINICAL PHENOTYPES OF MYOCARDIAL ISCHEMIA-REPERFUSION INJURY

Background: Reperfusion is required for myocardial salvage yet itself injures the heart, and cardioprotective interventions that reduce infarct size experimentally have repeatedly failed to improve outcomes in patients. These interventions are evaluated against viability or infarct size alone, whereas ischemia-reperfusion (I/R) injury produces structural, biochemical, and contractile dysfunction in the same tissue. No in vitro new approach methodology (NAM), however, resolves all three within one system. Methods: A NAM was created within a heart-on-a-chip platform, which was constructed by culturing neonatal rat ventricular myocytes (NRVMs) on muscular thin films. Cardiomyocytes were subjected to normoxia, 2 hours of ischemia, and ischemia followed by 2 hours of reperfusion. Sarcomeric architecture was quantified by immunofluorescence, cardiomyocyte injury by LIVE/DEAD staining and cardiac troponin I release into conditioned media, while contractile stress and spontaneous beat frequency were recorded on the same films before and after each condition. Results: Under ischemia, z-line density decreased while architectural metrics were preserved, indicating cell loss rather than sarcomere disorganization. Furthermore, viability decreased, troponin elevated, and every contractile stress component declined, while spontaneous beat frequency was unchanged. Reperfusion fractured this uniform depression. Cell death and troponin release increased further, yet structure was unchanged from ischemia, so every functional change occurred on a depleted but architecturally intact cardiomyocyte population. Systolic stress recovered partially, whereas diastolic stress exceeded baseline, leaving active stress suppressed despite oxygen recovery. Beat frequency increased with pronounced variability. Conclusions: This heart-on-a-chip NAM resolved structural, biochemical, and contractile injury that global indices conflate, distinguishing ischemic from reperfusion pathophysiology. Interestingly, individual readouts corresponded to distinct clinical syndromes of ischemic injury, positioning this platform for future testing of cardioprotective candidates against the full injury phenotype.

physiology↗